No connection

Search Results

ANIK vs OGI

ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%
OGI
Organigram Global Inc.
BEARISH
Price
$1.52
Market Cap
$209.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ANIK
--
OGI
13.82
Forward P/E
ANIK
35.5
OGI
84.44
P/B Ratio
ANIK
1.37
OGI
0.77
P/S Ratio
ANIK
1.82
OGI
0.75
EV/EBITDA
ANIK
-29.07
OGI
47.95

Profitability

Gross Margin
ANIK
56.56%
OGI
35.61%
Operating Margin
ANIK
2.11%
OGI
-5.38%
Profit Margin
ANIK
-9.64%
OGI
6.49%
ROE
ANIK
-6.71%
OGI
4.64%
ROA
ANIK
-3.52%
OGI
-1.47%

Growth

Revenue Growth
ANIK
0.0%
OGI
48.7%
Earnings Growth
ANIK
--
OGI
--

Financial Health

Debt/Equity
ANIK
0.18
OGI
0.02
Current Ratio
ANIK
4.72
OGI
2.73
Quick Ratio
ANIK
3.71
OGI
0.62

Dividends

Dividend Yield
ANIK
--
OGI
--
Payout Ratio
ANIK
0.0%
OGI
0.0%

AI Verdict

ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation
OGI BEARISH

OGI exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a negative operating margin of -5.38%. While the stock appears undervalued relative to its Graham Number ($2.21) and Price-to-Book ratio (0.77), the intrinsic value is significantly lower at $0.77. Strong top-line revenue growth of 48.7% is currently offset by a poor earnings track record and a concerning spike in Forward P/E (from 13.82 to 84.44), suggesting a projected collapse in earnings. The company is essentially a speculative play on revenue growth that has yet to prove operational sustainability.

Strengths
Strong YoY revenue growth of 48.70%
Very low leverage with a Debt/Equity ratio of 0.02
Trading below book value (P/B 0.77)
Risks
Critical financial health weakness (Piotroski F-Score 2/9)
Negative operating margin (-5.38%) indicating core business losses
Severe earnings volatility with an average surprise of -949.02% over the last 4 quarters

Compare Another Pair

ANIK vs OGI: Head-to-Head Comparison

This page compares Anika Therapeutics, Inc. (ANIK) and Organigram Global Inc. (OGI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile